Characterize hearing changes in Parkinson
- Trial ID
- NCT07083089
- Official Title
- Phenotyping of Audition in Patients With Early Stage of Neurodegenerative Disorders (Alzheimer and Parkinson' Diseases)
- Goal
- Characterize hearing changes in Parkinson
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Cilcare SAS
- Study Type
- INTERVENTIONAL
- Enrollment
- 309 participants
- Conditions
- Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD), Healthy Participants
- Interventions
- Thorough Hearing assessment
Plain-Language Summary
The goal is to map how peripheral and central hearing change in early Parkinson's and amnestic MCI, so researchers can spot auditory signs that might help with diagnosis or tracking. Participants undergo a comprehensive hearing and auditory processing assessment that measures ear function and how the brain handles sound, to compare patterns between PD, MCI, and healthy older adults. The study is enrolling French‑speaking adults aged 50 to 85, including people with early Parkinson's (diagnosed by 2015 criteria, MoCA ≥23), people with amnestic MCI (MoCA ≥23 or MMSE >24 with specific memory deficits), and cognitively normal controls (MoCA ≥26). People with conductive ear disease, cochlear implants, major psychiatric or neurological disorders, certain ototoxic drug use, type 2 diabetes, or other listed exclusions cannot join.
Locations
- CHU Gui de Chauliac, Montpellier, France
- CHU Nice, Nice, France
- CHU Carémeau, Nîmes, France
- Hospices Civils de Lyon, Hôpital des Charpennes, Villeurbanne, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Thorough Hearing assessment. The goal is to map how peripheral and central hearing change in early Parkinson's and amnestic MCI, so researchers can spot auditory signs that might help with diagnosis or tracking. Participants undergo a comprehensive hearing and auditory processing assessment that measures ear function and how the brain handles sound, to compare patterns between PD, MCI, and healthy older adults. The study is enrolling French‑speaking adults aged 50 to 85, including people with early Parkinson's (diagnosed by 2015 criteria, MoCA ≥23), people with amnestic MCI (MoCA ≥23 or MMSE >24 with specific memory deficits), and cognitively normal controls (MoCA ≥26). People with conductive ear disease, cochlear implants, major psychiatric or neurological disorders, certain ototoxic drug use, type 2 diabetes, or other listed exclusions cannot join.
- Who can participate?
- Participants must be between 50 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 8 months.